Barclays raised the firm’s price target on SpringWorks Therapeutics to $63 from $47 and keeps an Overweight rating on the shares post the Q4 report. The firm cites the revenue beat, raised outer year estimates, and a clearer path to profitability for the target increase.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Therapeutics price target raised to $59 from $54 at Goldman Sachs
- SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics reports Q4 EPS ($1.44), consensus ($1.24)
- SpringWorks Therapeutics price target raised to $70 from $60 at Wedbush
- SpringWorks Therapeutics to Present at Upcoming Investor Conferences
